NDA 050417 · Casper Pharma LLC
Lumi-Sporyn
Bacitracin Zinc, Neomycin Sulfate, Polymyxin B Sulfate · Ophthalmic
Last checked: Nov 19, 2026Latest source record: May 21, 2020 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1971
May 10, 1971
Approved uses
1
Original approval plus efficacy supplements
Registered trials
45
8 Phase 3, 1 recruiting
FAERS reports
0
0 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
No structured label for this application in openFDA. Older and discontinued products often have none.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- May 10, 1971 Original approval
1 products under this application
- LUMI-SPORYN · BACITRACIN ZINC 400 UNITS/GM; NEOMYCIN SULFATE EQ 3.5MG BASE/GM; POLYMYXIN B SULFATE 10,000 UNITS/GM · OINTMENT, OPHTHALMIC · Prescription · TE AT
Clinical trials
Interventional ClinicalTrials.gov studies with "Bacitracin Zinc" as an intervention, any sponsor and status, largest first.
- Prevention of Arrhythmia Device Infection Trial (PADIT)Pivotal-lookingCompleted
Population Health Research InstituteAcademic, hospital or other
NCT01628666 · 12,814 participants · Start Dec 2012 · Primary completion Sep 8, 2017
Drug: Incremental; Conventional · For: Arrhythmia
Sites: Hamilton, Canada
- Vancomycin Powder and Dilute Povidone Iodine Lavage for Infection Prophylaxis in High Risk Total Joint ArthroplastyPivotal-lookingCompleted
NYU Langone HealthAcademic, hospital or other
NCT04075526 · 2,129 participants · Start Oct 1, 2019 · Primary completion Jan 1, 2024
Drug: Povidone iodine; Vancomycin powder · For: Osteoarthritis
Sites: Rancho Mirage, California; Denver, Colorado; Weston, Florida · 14 sites in all
- Perioperative Antibiotic Therapy to Prevent Cardiac Implantable Electronic Device Infections.Pivotal-lookingCompleted
Vanderbilt University Medical CenterAcademic, hospital or other
NCT02809131 · 1,010 participants · Start Apr 1, 2016 · Primary completion Mar 31, 2021
Drug: polymixin/bacitracin; cephalexin, or levofloxacin, or clindamycin and 1 more · For: Sick Sinus Syndrome; Complete Heart Block; Syncope and 1 more
Sites: Nashville, Tennessee
- Prevention of Arrhythmia Device Infection Trial (PADIT Pilot)Pivotal-lookingCompleted
Population Health Research InstituteAcademic, hospital or other
NCT01002911 · 500 participants · Start Dec 2009 · Primary completion Jan 2012
Drug: Cefazolin, Bacitracin, Cefalexin; Cefazolin · For: Arrythmias
Sites: Ste-Foy, Canada
- Topical Antibiotic Prophylaxis for EyelidsPivotal-lookingCompleted
University of California, San FranciscoAcademic, hospital or other
NCT03199911 · 401 participants · Start Oct 2, 2017 · Primary completion Nov 14, 2019
Drug: Topical Antibiotic Product; Topical Non-Antibiotic Ointment · For: Antibiotic Side Effect; Eyelid; Wound; Eyelid Diseases and 6 more
Sites: San Francisco, California
- The Effects of Post-Operative Interventions on Surgical Site Occurrences in AWRPivotal-lookingRecruiting
Ohio State UniversityAcademic, hospital or other
NCT04906408 · 300 participants (planned) · Start Sep 17, 2021 · Primary completion May 1, 2028
Drug: Traditional · For: Abdomen Hernia
Sites: Columbus, Ohio
- Patient-Centered Comparative Effectiveness Research (CER) Study of Home-based Interventions to Prevent CA-MRSA Infection RecurrencePivotal-lookingStatus unknown
Clinical Directors NetworkResearch network
NCT02566928 · 278 participants (planned) · Start Oct 2015 · Primary completion Nov 2018
Drug: 2% mupirocin ointment · For: Methicillin-Resistant Staphylococcus Aureus; Recurrence; Staphylococcal Skin Infections and 1 more
Sites: Brooklyn, New York; New York, New York; The Bronx, New York · 6 sites in all
- Prevention of Arrhythmia Device Infection Trial (PADIT)Pivotal-lookingCompleted
Population Health Research InstituteAcademic, hospital or other
NCT01613092 · 241 participants · Start May 2011 · Primary completion Nov 2013
Drug: Incremental; Cefazolin · For: Arrhythmia
Sites: Hamilton, Canada; Ottawa, Canada
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
No FAERS reports name this application.
FAERS reports by year
By the date FDA received the report.
No reports.
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Topical antibiotics for preventing surgical site infection in wounds healing by primary intention.
Heal CF, Banks JL, Lepper PD, et al. · Cochrane Database Syst Rev 2016 · Meta-Analysis, Research Support, Non-U.S. Gov't
- Prospective evaluation of topical antibiotics for preventing infections in uncomplicated soft-tissue wounds repaired in the ED.
Dire DJ, Coppola M, Dwyer DA, et al. · Acad Emerg Med 1995 · Clinical Trial, Comparative Study
- Chemotherapy for giardiasis: randomized clinical trial of bacitracin, bacitracin zinc, and a combination of bacitracin zinc with neomycin.
Andrews BJ, Panitescu D, Jipa GH, et al. · Am J Trop Med Hyg 1995 · Clinical Trial, Randomized Controlled Trial
- A newly formulated topical triple-antibiotic ointment minimizes scarring.
Berger RS, Pappert AS, Van Zile PS, et al. · Cutis 2000 · Clinical Trial, Randomized Controlled Trial
- Postprocedural wound-healing efficacy following removal of dermatosis papulosa nigra lesions in an African American population: a comparison of a skin protectant ointment and a topical antibiotic.
Taylor SC, Averyhart AN, Heath CR · J Am Acad Dermatol 2011 · Randomized Controlled Trial
Sponsor: Casper Pharma LLC
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.